Search - tctmd.com

Displaying 21 - 40 of 77

Sort: Relevancy | Date

Presentation TCT 2021

Oral Anticoagulation Should Be the Default Strategy After LAAC

Presenter: Matthew J. Price

November 06, 2021

News Conference News TCT 2021

Magnetic Endoscopy Capsule Reveals GI Damage Surprises From Antiplatelets

Caitlin E. Cox

November 06, 2021

News Conference News TCT 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

Shelley Wood

November 05, 2021

News Conference News TCT 2021

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

Todd Neale

November 05, 2021

Presentation TCT 2021

PRAGUE-17: Three-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure Versus Direct Acting Oral Anticoagulation in Patients With Atrial Fibrillation

Presenter: Pavel Osmancik

November 05, 2021

News Conference News TCT 2021

LAA Closure Feasible in Patients With Thrombus: Registry

Michael O'Riordan

October 13, 2021

News Conference News TCT 2020

Valve Disease Plus COVID-19 Often a Lethal Combination, Registry Shows

Caitlin E. Cox

October 14, 2020

News Conference News TCT 2020

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

L.A. McKeown

October 14, 2020

News Conference News TCT 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Michael O'Riordan

September 28, 2019

Presentation TCT 2019

A Randomized Trial of Short-Course Dual Antiplatelet Therapy vs. Oral Anticoagulation to Prevent Cerebral Embolism After Transcatheter Aortic Valve Implantation

Presenter: Victor Alfonso Dias

September 28, 2019

News Conference News TCT 2019

Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT

Michael O'Riordan

September 27, 2019

News Opinion Editor's Corner TCT 2019

TCT 2019 Day Two: Transcatheter Valves, New and Old

Shelley Wood

September 27, 2019

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Todd Neale

September 26, 2019

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

Todd Neale

September 24, 2018

News Opinion Editor's Corner TCT 2018

TCT 2018, Day Three: Intravascular Imaging and Anticoagulation

Shelley Wood

September 24, 2018

Presentation TCT 2018

OAC-ALONE: A Randomized Trial of Oral Anticoagulation With vs Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation Beyond One Year After Coronary Stent Implantation

Presenter: Gregg W. Stone, Yukiko Nakano

September 24, 2018

Presentation TCT 2018

Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation

Presenter: Davide Capodanno, Giulio Stefanini, Robert A. Byrne

September 23, 2018

Presentation TCT 2018

US and ESC Guidelines and Consensus on Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing PCI

Presenter: Davide Capodanno, Giulio Stefanini, Dominick J. Angiolillo

September 23, 2018

Presentation TCT 2018

In 2018 When Is Warfarin Therapy Required vs Acceptable, and How Should it Be Dosed After PCI?

Presenter: Davide Capodanno, Giulio Stefanini, Freek W.A. Verheugt

September 23, 2018

Presentation TCT 2018

Has PIONEER and REDUAL Changed My Practice? What Are the Outstanding Issues?

Presenter: Davide Capodanno, Giulio Stefanini, C. Michael Gibson

September 23, 2018

Advertisement

Oral Anticoagulation Should Be the Default Strategy After LAAC

Magnetic Endoscopy Capsule Reveals GI Damage Surprises From Antiplatelets

More DAPT Duration Data, More Calls to Tailor to Individual Patients

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

PRAGUE-17: Three-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure Versus Direct Acting Oral Anticoagulation in Patients With Atrial Fibrillation

LAA Closure Feasible in Patients With Thrombus: Registry

Valve Disease Plus COVID-19 Often a Lethal Combination, Registry Shows

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

A Randomized Trial of Short-Course Dual Antiplatelet Therapy vs. Oral Anticoagulation to Prevent Cerebral Embolism After Transcatheter Aortic Valve Implantation

Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT

TCT 2019 Day Two: Transcatheter Valves, New and Old

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

TCT 2018, Day Three: Intravascular Imaging and Anticoagulation

OAC-ALONE: A Randomized Trial of Oral Anticoagulation With vs Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation Beyond One Year After Coronary Stent Implantation

Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation

US and ESC Guidelines and Consensus on Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing PCI

In 2018 When Is Warfarin Therapy Required vs Acceptable, and How Should it Be Dosed After PCI?

Has PIONEER and REDUAL Changed My Practice? What Are the Outstanding Issues?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content